YY 0861-2024Ophthalmic optics - Ophthalmic viscosurgical devices (English PDF)
眼科光学 眼用粘弹剂
Open the YY 0861-2024 preview as PDF
This is a limited preview
Buy now to download the full PDF (17 pages)
Issued by
NMPA
Level / Type
Industry · Mandatory
Issue date
July 8, 2024
Implementation date
July 20, 2027
Scope
YY 0861-2024 is the English-translated version of 眼科光学 眼用粘弹剂.
YY 0861 is the mandatory standard for the ophthalmic viscosurgical device, the viscoelastic gel injected into the eye during cataract and other anterior segment surgery to maintain space, protect the corneal endothelium and manipulate tissue. It is usually hyaluronate-based, and its rheology is the product: the balance of cohesion and dispersion decides whether it stays where it is put, whether it coats and protects, and how completely it can be removed at the end of the case, since retained viscoelastic raises intraocular pressure. The YY prefix without the /T suffix makes compliance compulsory in China. For a manufacturer or an importer of OVDs seeking Chinese registration, this is the governing product standard.
Document preview — YY 0861-2024
National Standard of the People's Republic of China
- ICS
- 11.040.70
- Classification
- C40
- Replacing
- YY 0861-2011
Issued by: National Medical Products Administration
Contents
- 1 Scope1
- 2 Normative references1
- 3 Terms and Definitions2
- 4 Expected Performance3
- 5 Design attributes3
- 5.1 General requirements3
- 5.2 Ingredient characteristics4
- 5.3 Finished product characteristics4
- 5.4 Availability6
- 6 Design Evaluation6
- 6.1 General requirements6
- 6.2 Biological safety assessment6
- 7 Sterilization7
- 8 Product Stability8
- 9 Conveyor System Integrity and Performance8
- 10 Packaging8
- 10.1 Damage prevention during storage and transportation8
- 10.2 Maintaining Sterility During Transport8
- 10 Reference13
Foreword
This document is in accordance with the provisions of GB/T 1.1-2020 "Guidelines for standardization work Part
1.Structure and drafting rules for standardization documents" Drafting. This document replaces YY 0861-2011 "Ophthalmic Optical Viscoelastics". Compared with YY 0861-2011, in addition to structural adjustments and compilation In addition to logical changes, the main technical changes are as follows:
--- Deleted the definition of "lost to follow-up cases" (see
3.5 of the.2011 edition);
--- Changed the definition of "primary packaging" (see 3.6,
3.7 of the.2011 edition);
--- Added the definition of "surgical implant" (see 3.11);
--- Changed "Expected Performance" (see Chapter 4, Chapter 4 of the.2011 edition);
--- Changed the "General requirements" of design attributes (see 5.1,
5.1 of the.2011 edition);
--- Changed "Ingredient Characteristics" (see 5.2,
5.2 of the.2011 edition);
--- Changed "Chemical and biological pollutants" (see 5.3.3,
5.3.3 of the.2011 edition);
1 Scope
YY 0861 is the mandatory standard for the ophthalmic viscosurgical device, the viscoelastic gel injected into the eye during cataract and other anterior segment surgery to maintain space, protect the corneal endothelium and manipulate tissue. It is usually hyaluronate-based, and its rheology is the product: the balance of cohesion and dispersion decides whether it stays where it is put, whether it coats and protects, and how completely it can be removed at the end of the case, since retained viscoelastic raises intraocular pressure. The YY prefix without the /T suffix makes compliance compulsory in China. For a manufacturer or an importer of OVDs seeking Chinese registration, this is the governing product standard.
This document specifies the expected performance, design attributes, design evaluation, sterilization, product stability, and delivery system integrity of ophthalmic viscoelastics. and performance, packaging and information provided by the manufacturer. This document applies to viscoelastics for ophthalmic use (hereinafter referred to as "viscoelastics").
2 Normative references
The contents of the following documents constitute essential clauses of this document through normative references in this document. For referenced documents without a date, only the version corresponding to that date applies to this document; for referenced documents without a date, the latest version (including all amendments) applies to This document.
GB/T 16886.1 Biological evaluation of medical devices Part
1.Evaluation and testing in the risk management process ( GB/T 16886.1- 2022, ISO 10993-1.2018,IDT)
GB/T 16886.6 Biological evaluation of medical devices Part
6.Local reaction test after implantation ( GB/T 16886.6-2022, ISO 10993-6.2016, IDT)
GB/T 16886.7 Biological evaluation of medical devices Part
7.Ethylene oxide sterilization residues ( GB/T 16886.7-2015, ISO 10993-7.2008, IDT)
GB/T 16886.9 Biological evaluation of medical devices Part
9.Qualitative and quantitative framework for potential degradation products ( GB/T 16886.9-2022, ISO 10993-9.2019,IDT)
GB/T 16886.16 Biological evaluation of medical devices Part
16.Toxicokinetic study design of degradation products and leachables ( GB/T 16886.16-2021, ISO 10993-16.2017,IDT)
GB 18278.1 Sterilization of health care products by moist heat Part
1.Development, validation and routine control of sterilization processes for medical devices Request ( GB 18278.1-2015, ISO 17665-1.2006, IDT)
GB 18279 Sterilization of healthcare products - Development, validation and routine control requirements for ethylene oxide sterilization processes for medical devices ( GB 18279-2023, ISO 11135.2014, MOD)
3 Guide to dose measurement ( GB/T 18280.3-2015, ISO 11137-3.2006, IDT)
GB/T 19633.1 Terminally sterilized medical device packaging Part
1.Requirements for materials, sterile barrier systems and packaging systems ( GB/T 19633.1-2015, ISO 11607-1.2006,IDT)
GB/T 42062 Application of medical device risk management to medical devices ( GB/T 42062-2022, ISO 14971.2019, IDT)
YY/T 0567.1 Aseptic processing of health care products Part
......
This preview omits tables, figures, formulas and parts of the technical clauses. The complete document — 17 pages — is available in the English PDF.
Referenced standards
Normative references
- GB/T 16886.1Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process
- GB 18280.1-2015Sterilization of health care products - Radiation - Part 1: Requirements for the development
ISO 10993 · GB/T 16886.6-2022 · GB/T 16886.7-2015 · GB/T 16886.9-2022 · GB/T 16886.16-2021 · GB 18278.1-2015 · ISO 17665 · GB 18279-2023 · ISO 11135.2014 · ISO 11137 · GB 18280.2-2015 · GB/T 18280.3
Editions of YY 0861
| Edition | Title | Revision | Status |
|---|---|---|---|
| YY 0861-2024 | Ophthalmic optics - Ophthalmic viscosurgical devices | current edition | Current |
| YY 0861-2011 | Ophthalmic optics - Ophthalmic viscosurgical devices | previous edition | In force until 2027-07-20 |
This page sells the current edition, YY 0861-2024. Earlier editions are listed for reference only.
How to Buy YY 0861-2024
- 1Add to cart. Click the "Buy YY 0861-2024" button on this page. You can add more standards before checkout.
- 2Checkout. Enter your email and billing details. Payment is processed securely by Stripe (cards, Apple Pay, Google Pay supported).
- 3Instant delivery (0–9 sec). Delivery is automatic: within seconds of payment you'll receive an email with a secure download link. The link stays valid for 72 hours.
- 4Invoice included. A tax invoice is attached to the confirmation email. Need a custom invoice? Contact us.
Related Standards
GB/T 16886.1-2022 — Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process
GB/T 16886.10-2024 — Biological evaluation of medical devices - Part 10: Tests for skin sensitization
YY 0017-2026 — Implants for osteosynthesis - Metallic bone plates
Secure payment via Stripe
Payments accepted
YY 0861-2024
$245.00